PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
R&D reduction while AVXL shows 22.05% growth. Joel Greenblatt would examine competitive risk.
-14.34%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
Other expenses reduction while AVXL shows 5832.87% growth. Joel Greenblatt would examine efficiency.
-7.72%
Operating expenses reduction while AVXL shows 14.64% growth. Joel Greenblatt would examine advantage.
-7.72%
Total costs reduction while AVXL shows 14.64% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
D&A reduction while AVXL shows 16.76% growth. Joel Greenblatt would examine efficiency.
7.65%
EBITDA growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Operating income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
158.44%
Other expenses growth less than half of AVXL's 11567.45%. David Dodd would verify if advantage is sustainable.
12.50%
Pre-tax income growth below 50% of AVXL's 50.59%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Net income growth below 50% of AVXL's 50.77%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
15.94%
EPS growth below 50% of AVXL's 54.15%. Michael Burry would check for structural issues.
15.94%
Diluted EPS growth below 50% of AVXL's 54.15%. Michael Burry would check for structural issues.
4.10%
Share count reduction below 50% of AVXL's 7.20%. Michael Burry would check for concerns.
4.10%
Diluted share reduction below 50% of AVXL's 7.20%. Michael Burry would check for concerns.